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Leukotriene E4 (LTE4) is implicated in asthma pathophysiology and possibly in chronic
obstructive pulmonary disease (COPD) as one of the causes of persistent bronchoconstric-
tion and mucus hypersecretion. Cigarette smoking stimulates cysteinyl leukotrienes
(CysLTs) production. We investigated whether LTE4 is equally increased in asthma and
COPD and whether smoking significantly affects LTE4 levels. Secondary outcomes involved
correlations with inflammatory and functional parameters.
We studied 40 patients with COPD [20 smokers], 40 asthmatics [20 smokers] and 30 healthy
subjects [15 smokers]. Spirometry (FEV1% pred., FEV1/FVC) was performed, urine was
collected for measurement of LTE4 and creatinine, induced sputum was collected for
differential cell counts and serum for ECP.
LTE4/creatinine levels (pg/mg) [mean (SD)] were increased in asthmatic patients compared
to COPD and controls, [125.6(54.5) vs. 54.5(19) vs. 55.9(18.9) pg/mg, respectively,
Po0.0001 for asthma]. Smoking significantly affects LTE4 levels only in asthmatic patients
[164 (48) vs. 87 (26.3), Po0.0001 for smokers]. The only significant correlation was
between eosinophils in induced sputum and LTE4/creatinine levels in asthmatics.
In conclusion, patients with asthma presented higher LTE4 values compared to normals and
patients with COPD. Smoking significantly affects LTE4 values only in asthmatics indicating
a different underlying CysLTs inflammatory process in this condition.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
8954603;
kides).Introduction
Cysteinyl leukotrienes (CysLTs) are a group of inflammatory
mediators, which has received interest in the recent years.
CysLTs (leukotrienes C4, D4 and E4) are central mediators in
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Leukotriene E4 in urine in patients with asthma and COPD 827asthma pathophysiology. Several inflammatory cells have
the biosynthetic capacity to produce CysLTs and Leukotriene
E4 (LTE4) is a stable end product of CysLTs metabolism in the
human lung. Urine LTE4 is a reliable marker of endogenous
CysLTs formation and measurement of LTE4 offers a
possibility to monitor changes in the rate of CysLTs
production.1 Cigarette smoking stimulates CysLTs production
in animal models but also in humans.2 The role of CysLTs in
chronic obstructive pulmonary disease (COPD) remains
uncertain despite previous but limited evidence which
indicates increased production in different fluids in this
disorder.3,4 However, there is evidence that CysLTs increase
microvascular permeability, evoke mucus hypersecretion
and are potent smooth muscle constriction agents,5 features
that are present in the airways of COPD patients, and this
suggests that they might play a role in this disorder.
We tested the hypothesis that LTE4 values are equally
increased in both asthma and COPD patients, and smoking
habit significantly affects the above measurements. There-
fore, we assessed the levels of LTE4 in the urine of patients
with COPD and asthma, as well as in healthy controls, in an
attempt to clarify the in vivo role of this mediator. Smoking
as a possible factor that might affect LTE4 values was also
tested after subdividing the study groups according to their
smoking habit. Additionally, we investigated whether airway
or systemic eosinophilic inflammation is implicated in the
pathophysiology of this mediator in the two diseases, by
assessing sputum differential cell counts and serum eosino-
philic cationic protein (ECP) levels. Finally, we examined
whether the functional status, as assessed by forced
expiratory volume in 1 s (FEV1%) predicted and the FEV1/
FVC (FVC—forced vital capacity) ratio, is implicated in the
measurements of LTE4.
Materials and methods
Subjects
Subjects’ characteristics are summarized in Table 1. The
diagnosis of COPD was established according to the GOLD
Guidelines,6 whereas the GINA Guidelines were used for the
diagnosis of asthma.7 All subjects in the three study groups
were subdivided according to their smoking habit (for COPDTable 1 Subject characteristics.
Controls
(n ¼ 30) 9F–21M
Age (years) 48 (8.5) (33–67)
BMI (kg/m2) 26 (3.5) (20–35)
FEV1 (% pred) 99 (10.5) (85–123)
FEV1/FVC ratio (%) 99.5 (9) (89–125)
Smoking habit (pack-years) n ¼ 15 38 (9) (19–80)
ECP 6(2) (3–9)
Eosinophils (%) ND
Neutrophils (%) ND
Data are presented as mean (SD) with ranges in parenthesis.
ND ¼ not done, M ¼ male, F ¼ female.
Smoking habit refers only to the subgroups of current smokers inpatients this subdivision referred to current and ex-
smokers). A total of 145 subjects were initially recruited
in order to achieve the final number of patients.
Forty COPD patients (20 current smokers, all non-atopic
and steroid-naı¨ve) were recruited. All COPD patients were
characterized by the absence of eosinophils in induced
sputum. All patients were receiving occasionally short acting
b2-agonists as relief medication. Ex-smokers with COPD
stopped smoking at least 2 years before entering the study.
Forty atopic asthmatics, matched for age, BMI and lung
function with COPD patients (20 current smokers, 20 never
smokers, matched for age, BMI, lung function and smoking
habit with the COPD patients who were current smokers; all
steroid-naı¨ve), were also studied. All asthmatic patients had
positive bronchodilation tests (increase of pre-bronchodila-
tor FEV1412% after administration of salbutamol at dose
400mcg by meter dose inhaler). They were occasionally
receiving short-acting b2-agonists as relief medication.
Thirty normal subjects (15 current smokers, 15 never
smokers, matched for the smoking habit with the respective
asthmatic and COPD smokers), with no history of any
disease, served as controls. All were non-atopic, had normal
lung function and negative bronchial challenge testing, and
none of them was receiving any kind of medication at the
time of the study. Normal subjects were younger compared
to asthma and COPD patients since it is difficult to find
healthy subjects without any comorbidities in the age of 65
years old.
All patients were clinically stable, i.e. they had no
evidence of acute exacerbation for at least 4 weeks prior to
the study. None of our patients was receiving any anti-
inflammatory treatment (including corticosteroids, long-
acting b2 agonists, or leukotriene receptor antagonists),
theophylline, inhaled or oral mucolytics, or long-term
oxygen therapy. Atopy was defined by the high values of
total IgE and on the basis of positive skin tests to six common
aeroallergens.Study protocol details
Lung function measurements were performed in all subjects
one day before the urine and blood collection and sputum
induction. In all subjects, the collection of urine and bloodAsthma COPD
(n ¼ 40) 14F–26M (n ¼ 40) 12F–28M
63 (14) (31–80) 64 (8) (49–81)
28.4 (4) (20–40) 27(4) (21–34)
71 (16) (42–98) 67 (9) (49–85)
68 (4) (59–76) 64 (3) (57–70)
n ¼ 20 37.5 (10) (20–55) n ¼ 20 41 (11) (25–63)
14.5(7) (5–35) 6.5(2) (3–10.5)
7.5 (4) (2–17) 0
28.5 (6) (22–40) 64(7) (45–73)
each group.
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E. Gaki et al.828preceded the sputum induction procedure, in order to avoid
any effect of sputum induction procedure on the urine and
blood measurements. All subjects were asked not to smoke
2 h before each procedure. In order to ensure the subjects’
compliance to this recommendation, they were asked to
stay in our laboratory for 2 h under the supervision of one of
the investigators. Sputum induction was not performed in
normal subjects. Metacholine test was performed only in
normal subjects on a separate day of the protocol. All
subjects were asked not to receive short-acting bronchodi-
lators at least 12 h before the collection of samples and the
lung function tests.
LTE4/creatinine values were compared among patients
with COPD, patients with asthma and normal subjects.
Similar comparisons were performed in the study subgroups.
Correlations between LTE4/creatinine values and study
parameters were also performed in all study groups.
All subjects were recruited from the outpatient clinics of
the Athens Veterans Hospital. This is a general hospital that
serves veterans and civilians. The Scientific Committee of
the hospital approved the study protocol, and all partici-
pants gave written informed consent.
Metacholine challenge
Bronchial hyperresponsiveness to metacholine was mea-
sured and performed by a rapid metacholine inhalation test
for the determination of PD20, as previously described for
histamine.8 PD20 was determined by linear interpolation on
a semi-logarithmic scale. The test was performed according
to the instructions established by the American Thoracic
Society guidelines.9
Lung function
Pulmonary function tests were measured with a dry
spirometer (Vica-test, Model VEP2; Mijnhardt; Rotterdam,
Holland). FEV1 and FVC were measured according to the
American Thoracic Society guidelines.10
Sputum induction and processing
Sputum was induced as previously described.11 Subjects
were asked to blow their noses, rinse their mouths, and
swallow the water in the aerosol to minimize contamination
with postnasal drip and saliva. An induction procedure using
inhalation of an aerosol of hypertonic saline solution (3.5%)
generated by a DeVilbiss ultrasonic nebulizer (2696 Somer-
set PA, USA) was chosen. Induction was performed for
periods of 30 s, and 1, 2, 4 and 8min. The patients were
asked to expectorate sputum after the 4 and 8min period.
At least 2mL of sputum were collected in a sterile container.
The person who did the differential cell counts in sputum
(G.P.) was not aware of the clinical and functional status of
the patients or the results of bronchial challenge testing.
LTE4 measurements
LTE4 concentrations were measured in a non-purified urine
morning sample with a specific competitive enzymeimmunoassay (EIA) (Cayman Chemical; Ann Arbor, MI, USA,
No. 520411). The detection limit of the assay was 25 pg/mL.
The results were normalized to the creatinine concentration
determined in the same sample and the LTE4/creatinine
ratios were used for subsequent studies. All urine samples
were tested for protein, bilirubin, ketone, urobilinogen,
glucose and hemoglobin and if any of these substances were
presented the sample was excluded from the study.
According to manufacturer’s guidelines and in order to
check the need of purification, all samples diluted 1:3 with
distilled water. LTE4 was measured in diluted and undiluted
samples. The two different dilutions of the samples showed
differences less than 18% in the final calculated LTE4
concentration, so the samples were measured without
purification.
Creatinine measurement
Creatinine concentration in urine was measured with a
kinetic method. The complex formed by creatinine and
picric acid (8.8mmol/L) in an alkaline medium (NaOH 0.4M)
was measured for 1min at 492 nm.
ECP measurement
The concentrations of ECP in the serum were determined by
a specific enzyme immuno-assay (Pharmacia Diagnostics AB;
Uppsala, Sweden) in an auto analyzer (Uni CAP 100) with a
lower limit of detection of 2.0 mg/L.
LTE4/creatinine repeatability measurements
Repeatability of LTE4/creatinine measurements was evalu-
ated in 20 subjects [4 controls (2 smokers),8 COPD patients
(4 from each subgroup) and 8 asthmatics (4 smokers)].
Repeatability of LTE4/creatinine measurements was tested
in samples from the same subjects collected on two
consecutive days.
Statistical analysis
Data are expressed as mean (SD), unless otherwise men-
tioned. Values among three or more groups were evaluated
using one-way analysis of variance (ANOVA) with an
appropriate post hoc test for multiple comparisons (Bonfer-
roni). For comparisons between two groups, Mann–Whitney
U tests were used. Spearman’s correlation coefficient was
used to investigate correlations between parameters.
Repeatability of LTE4/creatinine measurements was as-
sessed with the Bland and Altman test.12 A P-value o0.05
was considered significant.
Results
Subjects characteristics in induced sputum
Asthmatic patients were mainly characterized by a pre-
dominant eosinophilia in induced sputum whereas COPD
patients were characterized by a predominance of neutro-
philic inflammation (Table 1). Asthmatic smokers presented
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Leukotriene E4 in urine in patients with asthma and COPD 829with significantly higher values of % eosinophils in induced
sputum compared to non-smokers (Table 2, Po0.003).
Asthmatic smokers presented a trend for higher values of
% neutrophils in induced sputum compared to non-smokers,
that was marginally statistically significant (Table 2,
P ¼ 0.048). No significant differences were observed be-
tween current and ex-smokers patients with COPD in regard
to % neutrophils in induced sputum (Table 2, P ¼ 0.79)
LTE4/creatinine levels in major study groups
The levels of LTE4/creatinine (pg/mg) were increased in
asthmatic subjects compared to COPD and controls
[125.6(54.5) vs. 54.5(19) vs. 55.9(18.9) pg/mg, respectively,
Po0.0001 for asthma, Fig. 1]. No statistically significant
difference was found between COPD patients and normal
subjects [54.5(19) vs. 55.9(18.9) pg/mg, P ¼ 0.3, Fig. 1].
Effect of smoking
The levels of LTE4/creatinine (pg/mg) were increased in
asthmatic smokers compared to non-smokers [164 (48) vs. 87
(26.3) pg/mg, Po0.0001, Fig. 2]. No significant difference
was observed between smokers and non-smokers in the
COPD and control groups [58.3 (23) vs. 50.5(13) pg/mg,
P ¼ 0.4, 56(20) vs. 56 (18), P ¼ 0.83, respectively, Fig. 2].
However, a trend for higher values in COPD smokers
compared to ex-smokers was evident.
Correlations
Major correlation data are summarized in Table 3. Briefly,
the values of LTE4/creatinine presented a significant
correlation with eosinophils in induced sputum in asthmatics
(r ¼ 0.83, Po0.0001). This significant correlation was also
observed in smoking asthmatics, but was not expressed in
asthmatic non-smokers (Table 3, Figs. 3A and B). No
correlation with ECP levels was found. No significant
correlation was observed between the levels of LTE4/
creatinine and any of the parameters tested in COPD
patients. No significant correlation was observed between
LTE4 and the degree of lung function impairment or the
smoking habit in pack-years in all study groups. Neutrophils
in COPD patients did not present any significant correlations
with LTE4/creatinine (r ¼ 0.02, P ¼ 0.77).
Repeatability of LTE4/creatinine measurements
The measurements of LTE4/creatinine on 2 consecutive days
presented good repeatability. LTE4/creatinine on days 1 and
2 were 80.96(52) pg/mg and 82.04(52) pg/mg, respectively.
The correlation between LTE4/creatinine measurements on
two consecutive days was significant (r ¼ 0.94, Po0.0001).
The mean difference with limits of agreement was
1.0874.9 (mean72 SD) in the Bland and Altman plot.
Discussion
In this prospective cross-sectional study we have found
significant elevation of LTE4 levels in the urine of patients
ARTICLE IN PRESS
Table 3 Correlations of LTE4 in COPD and asthmatic patients a
LTE4
Asthma COPD
r P-value r P-va
FEV1 (% predicted) 0.02 0.80 0.04 0.74
FEV1/FVC ratio 014 0.35 0.21 0.10
Eosinophils (%) 0.83 o0.0001 ND ND
Smoking (py) ND ND ND ND
ECP (mg/L) 0.10 0.50 0.002 0.83
Neutrophils 0.03 0.86 0.02 0.77
Bold letters indicate significant correlations.
ND ¼ not done.
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Figure 1 LTE4/creatinine concentration in control subjects [all
n ¼ 30 ’], patients with asthma [all n ¼ 40 m, and patients
with COPD [all n ¼ 40., Each symbol represents one individual.
Horizontal bars represent mean values. See text for details.
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Figure 2 LTE4/creatinine concentration in non-smoking con-
trol subjects [n ¼ 15&], smoking control subjects [n ¼ 15’],
non-smoking patients with asthma [n ¼ 20 ,], smoking patients
with asthma [n ¼ 20m], ex-smokers with COPD [n ¼ 20 J] and
smokers with COPD [n ¼ 20 K]. Each symbol represents one
individual. Horizontal bars represent mean values. S ¼ smoking,
NS ¼ non-smoking, ES ¼ Ex-smoking. See text for details.
E. Gaki et al.830with asthma compared to matched COPD patients and
healthy controls. Smoking habit significantly affects LTE4
levels only in asthmatic subjects. The values of LTE4 in urine
present significant correlations with eosinophils in induced
sputum only in asthmatics; interestingly, the absence of
smoking habit seems to affect negatively the above
significance. The measurements of LTE4/creatinine on 2
consecutive days are repeatable.
CysLTs are synthesized from arachidonic acid through a
5-lipoxygenase pathway and are mainly generated by many
inflammatory cells, particularly eosinophils, mast cells and
macrophages. The implication of LTE4 in asthmatic inflam-
mation is well established, and the increased levels of LTE4
in the urine of asthmatic subjects reported in this study are
comparable to those published by previous investiga-
tors.13,14 However, this is the first study to our knowledge
that evaluates the levels of LTE4 in urine of patients with
COPD. Two previous studies have reported increased CysLTs
levels in patients with COPD; however, in the first study the
mediator that was used (LTC4) is not considered as a stable
end product in CysLT production,2 and in the second the
biological fluids studied did not represent sources which
would definitely express airway inflammation.15 Interest-
ingly, the levels measured were not significantly higher
compared to normal subjects, indicating that the
5-lipoxygenase pathway of arachidonic acid metabolism
may not be activated in COPD patients. The reason for this
observation might be attributed to the capability and/or the
activation state of the inflammatory cells which participate
in the CysLTs production. This is partially supported
by the findings of our study that show a positive correlation
between sputum eosinophils and LTE4 values in asthma
and the absence of any correlation between induced
sputum cells and LTE4 values in COPD. However, this positive
correlation might also express the CysLTs-induced prolonged
survival of eosinophils in the airways that contributes to
the maintenance of the inflammatory process in asthma.16
The absence of similar correlation with ECP might be related
to the low sensitivity of this mediator for the assess-
ment of eosinophilic inflammation. A previous observa-
tion, where the use of a CysLT1 receptor antagonist led to
improvement of some COPD patients with less fixed
airflow obstruction was not tested in this study,
since the methodology used did not include a propers well as in asthmatic smokers and non-smokers.
Asthma smokers Asthma non-smokers
lue r P-value r P-value
0.07 0.74 0.10 0.6
0.1 0.63 0.07 0.77
0.77 o0.0001 0.31 0.10
0.24 0.25 ND ND
0.21 0.73 0.08 0.71
0.04 0.81 0.06 0.88
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Figure 3 Correlations between the concentration of LTE4/creatinine and eosinophils (A) in asthmatic smokers (r ¼ 0.77, Po0.0001)
and (B) in asthmatic non-smokers (r ¼ 0.35, P ¼ 0.1).
Leukotriene E4 in urine in patients with asthma and COPD 831placebo-controlled design; thus, any conclusions arising
were not strong enough to confirm a potential role of CysLT1
receptor antagonists in COPD.17
Smoking affects significantly LTE4 levels in asthma but not
in COPD and normal subjects. The positive effect of smoking
in CysLTs production in asthma, irrespective of the degree of
smoking habit, might be related to the number and/or the
activation state of cells responsible for producing CysLTs.
Cells like alveolar macrophages and mast cells, which are
activated in asthma and also increased by smoking, might
stimulate the production of CysLTs via the preexisting
activated 5-lypoxygenase pathway. This theory is supported
by previous observations where in vivo data showed the
protective effect of a leukotriene receptor antagonist on
cigarette smoking-induced lung injury.18 Similar findings
regarding the concentration of the eicosanoid PGE2 in
smoking asthmatics19 indicated that eicosanoid metabolism
in asthmatics is significantly influenced by smoking. Data
from the present study showing absence of significant
correlation between eosinophils in induced sputum and the
levels of LTE4 in the urine of non-smoking asthmatics may
represent further evidence in this direction. However a
possible limitation of our study by combining the above
observations might be that they just represent the pro-
longed survival of eosinophils that is induced by the
increased CysLTs or the eosinophil-induced CysLTs produc-
tion. The above observation about the effect of smoking on
asthmatics might have practical implications, since it might
partially explain the difference in the response to inhaled
steroid treatment in smoking asthmatics, once the CysLTs-
related pathophysiology is not sensitive to the treatment
with steroids.20,21 Interestingly, the above observations
were not present in normal subjects and COPD patients.
This finding does not seem reasonable, but it could be
attributed to the previously inactivated 5-lipoxygenase
pathway. In normal subjects it might also be explained by
previous observations where the increase in LTE4 was
attributed to acute effects rather than to indirect effects
resulting from chronic smoking exposure, since 5-lipoxygen-
ase is not in a proper state to be activated and to produce
CysLTs.2 However, some previous data supports that smoking
in a dose-dependent manner significantly affects LTE4 values
in normal subjects.22The repeatability data presented in this study are similar
to data reported for COPD using another biological fluid,23
indicating that, in stable patients with chronic inflammatory
airway diseases and persistent inflammation, the measure-
ment of mediators involved in the inflammatory process may
be repeatable. This study presents one possible limitation,
regarding the measurement of LTE4 in urine, which was
performed by an EIA without purification. However, LTE4 has
been shown to be stable in urine samples stored at 20 1C
for months without the addition of preservatives. Addition-
ally, LTE4 levels in crude urine samples assessed by EIA have
been shown to present significant correlation with LTE4
measurements performed after purification on solid-phase
extraction followed by separation on reversed-phase high-
performance liquid chromatography24 and finally a specific
procedure assessing interference in diluted and undiluted
samples as suggested by the manufacturer was performed.
In summary, we report that patients with asthma present
higher urine LTE4 values compared to patients with COPD
and to healthy controls. Smoking in asthmatics seems to be a
critical parameter that might influence the above values.
Eosinophils as a cellular source or as a result of prolonged
survival are probably the key inflammatory cells in CysLTs-
related inflammatory process in smoking asthmatics.
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